Lifeboat Foundation

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from UConn Health report. The discovery could lead to new treatments for Type 2 diabetes and other metabolic diseases.

The cells in your body are constantly renewing themselves, with older cells aging and dying as new ones are being born. But sometimes that process goes awry. Occasionally damaged cells linger. Called senescent cells, they hang around, acting as a bad influence on other cells nearby. Their bad influence changes how the neighboring cells handle sugars or proteins and so causes metabolic problems.

Type 2 diabetes is the most common metabolic disease in the US. About 34 million people, or one out of every 10 inhabitants of the US, suffers from it, according to the Centers for Disease Control and Prevention (CDC). Most people with diabetes have insulin resistance, which is associated with obesity, lack of exercise and poor diet. But it also has a lot to do with senescent cells in people’s body fat, according to new findings by UConn Health School of Medicine’s Ming Xu and colleagues. And clearing away those senescent cells seems to stop diabetic behavior in obese mice, they report in the 22 November issue of Cell Metabolism. Ming Xu, assistant professor in the UConn Center on Aging and the department of Genetics and Genome Sciences at UConn Health, led the research, along with UConn Health researchers Lichao Wang and Binsheng Wang as major contributors. Alleviating the negative effects of fat on metabolism was a dramatic result, the researchers said.

https://www.youtube.com/watch?v=NCABjYITbco&feature=share

✅ Instagram: https://www.instagram.com/pro_robots.

You’re on the PRO Robots channel and in this episode we’re going to talk about a vacation in space. When will this cherished dream come true? How will such a trip take place, what will the preparation consist of, how much does a trip and service in space cost, what will be the food for the space tourists and what are the living conditions and dangers awaiting them — watch this video! Watch this episode to the end and write in the comments: would you dare to go on a space vacation?

Continue reading “What awaits us in the hotel in space and on the moon? | Is a vacation in orbit already a reality?” »

Can you imagine a brain and its workings being replicated on a computer? That is what the EBRAINS Cellular Level Simulation Platform aims to do. The Platform is available to researchers worldwide, so that they can compare their experimental results with model predictions and conduct investigations that are not possible experimentally.

Simulation also aims to replicate work on animal models, such as the mouse. In addition, the computing environment used for simulation offers the possibility of studying disease processes electronically.

However, the challenge is a complex one, as the human brain contains 86 billion brain cells (known as neurons) each with an average of 7,000 connections to other neurons (known as synapses). Current computer power is insufficient to model a entire human brain at this level of interconnectedness.

Without protein theft, the virus can’t get to the nucleus of nerve cells.

This is a farm in China.
This is a Mcdonalds in New York.
This is an apartment complex in Mumbai.
And this is a skyscraper in London.

What do all these have in common? Well as it turns out. All of these places’ successes or failures…
Economic booms or collapses…
And even population growth or famines…
Might soon be decided by the nation of Morocco.

Continue reading “How Morocco Secretly Controls China, India, The United States, And the World” »

Everyone talks about learning methods, but few people can find realistic and genuine methods that provide a net profit in the types of information and application.

Elon Musk has broken through that barrier by employing learning techniques that have been proven time and time again to be successful. Musk may be said to have taken use of his education by becoming a disruptor. He and his businesses have transformed entire industries, such as transportation, energy, and space.

He recently stated at a press conference that his plans for his biotech company, Neuralink, are proceeding well, implying that he will likely move his focus in the near future to yet another sector. Musk is, without even a doubt, a once-in-a-generation genius. Possibly on par with Nikola Tesla, Albert Einstein, and Isaac Newton. He tackles things in a different way than the typical entrepreneur.

The Food and Drug Administration approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height but has been polarizing among adults with short stature.

The treatment, developed by BioMarin Pharmaceutical, is a once-daily injection for children with achondroplasia, a rare genetic disorder that results in dwarfism and can lead to serious medical complications. In a pivotal clinical trial, patients who got the drug, called Voxzogo, grew 1.6 centimeters more over the course of a year than those who received placebo. That means patients who take Voxzogo throughout childhood are likely to reach heights similar to their peers who don’t have achondroplasia, according to BioMarin.

“It’s the difference between being able to drive a car or not, reaching stuff in closets, being able to take care of your hygiene,” said Jean-Jacques Bienaimé, BioMarin’s CEO. “It would make a huge difference for those patients. There’s no question about it.”

Skyrocketing demand for boxes and packing materials during the pandemic has slashed paper production across North America, and it couldn’t have come at a worse time for retail companies.

“We’re starting to hear, ‘We’re out of paper,’” said Polly Wong, president of San Francisco-based direct-marketing firm Belardi Wong, noting that some of her clients already missed their fall advertising campaigns due to issues at the printers. Wong estimates that 100 million catalogs will not be printed or reach U.S. homes in time for the year’s biggest spending season as a result. “It kind of put our industry up in a panic.”

With some mills converting to cardboard to meet the spike in e-commerce deliveries and others shutting down altogether, more than 2.5 million metric tons of North American printing and writing paper capacity — or nearly one-fifth of 2019 levels — has come offline since the start of last year. That’s according to Kevin Mason, managing director for ERA Forest Products Research, a financial research company that specializes in paper and forest products.

Transforming CT: Naeotom Alpha is the world’s first photon-counting CT scanner. (Courtesy: Siemens.